In cancer, cells proliferate rapidly, necessitating the continuous rewriting of epigenetic marks in daughter cells, so that inhibiting epigenetic machinery enzymes with DNMT or HDAC inhibitors can reactivate genes whose silencing is responsible for cancer aggressiveness and resistance to conventional therapies. The gene discussed is DNMT1; the disease is cancer.